New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
11:20 EDTVNDAVanda shares attractive amid negative sentiment, says Piper Jaffray
Piper Jaffray believes the negative sentiment surrounding shares of Vanda Pharmaceuticals presents an excellent entry point into the name. Piper says Vanda has yet to ramp its physician education efforts regarding Hetlioz and that the dug has the potential to be a multi-hundred million dollar product. The firm reiterates an Overweight rating on Vanda with a $21 price target.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
15:50 EDTVNDAVanda patent may meaningfully extend Hetlioz exclusivity, says Piper Jaffray
Subscribe for More Information
July 17, 2014
08:34 EDTVNDAVanda requests award of $539M in proceedings with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use